ConvaTec Group PLC (CTEC) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally.
Total Cash From Operating Activities Chart for ConvaTec Group PLC
ConvaTec Group PLC (CTEC) operating cash flow for FY2025 was GBP 479.9M, a 21.1% change from FY2024. ConvaTec Group PLC's operating cash flow grew from GBP 229.1M in 2013 to GBP 479.9M in 2025 (109.5% over 12 years). Operating cash flow compound annual growth rate: 5-year CAGR of 3.7%, 10-year CAGR of 16.9%.
Total Cash From Operating Activities (British Pounds)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- £4.48B
- Implied Share Price
- £2.30
- Enterprise Value
- £5.79B
- Revenue (TTM)
- £2.49B
- EBITDA
- £582.00M
- Profit Margin
- 4.98%
- Trailing P/E
- 45.92
- Forward P/E
- 15.75
- Price/Book (MRQ)
- 4.30
- Price/Sales (TTM)
- 1.80
- EV/EBITDA
- 17.25
- EV/Revenue
- 3.13
- Dividend Yield
- 3.24%
- Book Value
- £0.54
- Free Cash Flow (FY2025)
- £342.03M
- Free Cash Flow Yield
- 7.64%
Snapshot as of 15th August 2026 — not point-in-time controlled, may lag the live market by a few days.